It needs to be established if clinical anti-TIM-3 antibodies mediate ADCP and if this could be useful in the AML/MDS context where TIM-3 expression on LSCs or blasts may result in direct anticancer activity. The gene discussed is HAVCR2; the disease is myelodysplastic syndrome.